COMP <GO>
TLSA vs VTVT // EV/EBITDA & P/E VALUATION
Tiziana Life Sciences Ltd. (NASDAQ) VS. vTv Therapeutics Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: TLSA 2
— VTVT 0
■ METRIC PARITY
LAST: $0.67 (-16.25%) • MKT CAP: $101.8M
valuation
—
LAST: $24.15 (-4.05%) • MKT CAP: $99.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TLSA VS. VTVT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TLSA | VTVT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -24.21% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.5 | 32.8 | +1.70 | TLSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $101.8M | $99.5M | $2.3M | TLSA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TLSA REV | VTVT REV | TLSA GROSS % | VTVT GROSS % | TLSA FCF | VTVT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $91.9M | — | — | — | -$25.3M |
| FY 2024 | — | $1.0M | — | — | — | -$25.3M |
| FY 2023 | — | $71.4M | — | — | — | -$19.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TLSA // BETA —
VTVT // BETA —